Systematic Review of Survival Following Liver or Lung Metastasectomy for Metastatic Anal Squamous Cell Carcinoma

Overview

Journal Ann R Coll Surg Engl

Specialty General Surgery

Date 2024 Mar 18

PMID 38497793

Authors

L Hurt

E Barlow

M Davies

D A Harris

C Barrington

R L Harries

Affiliations

Soon will be listed here.

Abstract

Introduction: Metastatic anal squamous cell carcinoma (SCC) carries a poor prognosis and the evidence base for surgical resection of metastases remains limited. The aim of this study was to establish the survival outcomes for patients undergoing metastasectomy for anal SCC.

Methods: A systematic review was performed using the MEDLINE, Embase, Cochrane and PubMed databases. Studies were considered for inclusion in the review if they involved patients aged >18 years with a diagnosis of stage IV anal SCC who underwent metastasectomy for liver and/or lung metastases. The primary outcome measure was overall survival. Secondary outcome measures were disease free survival, early morbidity according to the Clavien-Dindo classification and quality of life, measured using a validated scoring tool. Risk of bias was assessed with the ROBINS-I (Risk Of Bias In Non-randomised Studies - of Interventions) tool.

Results: There were 10 studies with a total of 98 patients. There was heterogeneity in results reporting, with recurrence free survival the most reported outcome. For all studies reporting on liver metastasectomy, the one-year overall survival rate was 87%. In studies with adequate follow-up reported, the three and five-year overall survival rates were 53% and 38% respectively. Only one study reported on lung metastasectomy patients; the overall median survival was 24 months. None of the studies reported on quality of life measures. The ROBINS-I tool identified a critical risk of bias in six studies, a serious risk in one study and a moderate risk in three studies.

Conclusions: The evidence base for metastasectomy in metastatic anal SCC is limited. Further information is required to inform future treatment methods and use of a standardised outcomes reporting method is needed to support this.

References

Gurfinkel R, Walfisch S . Combined treatment of basaloid anal carcinoma using cisplatin, 5-fluorouracil and resection of hepatic metastasis. Tech Coloproctol. 2005; 9(3):235-6. DOI: 10.1007/s10151-005-0234-1. View

Salati S, Al Kadi A . Anal cancer - a review. Int J Health Sci (Qassim). 2013; 6(2):206-30. PMC: 3616949. DOI: 10.12816/0006000. View

Sousa T, Santos B, Belotto M, Peixoto R . Successful hepatectomy for metastatic squamous cell carcinoma of the anal canal-a case report. J Gastrointest Oncol. 2017; 7(6):E103-E106. PMC: 5177591. DOI: 10.21037/jgo.2016.11.06. View

Gnanajothy R, Warren G, Okun S, Peterson L . A combined modality therapeutic approach to metastatic anal squamous cell carcinoma with systemic chemotherapy and local therapy to sites of disease: case report and review of literature. J Gastrointest Oncol. 2016; 7(3):E58-63. PMC: 4880778. DOI: 10.21037/jgo.2015.11.02. View

Montagnani F, Crivelli F, Aprile G, Vivaldi C, Pecora I, De Vivo R . Long-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factors. Cancer Treat Rev. 2018; 69:11-20. DOI: 10.1016/j.ctrv.2018.05.010. View

Rao S, Sclafani F, Eng C, Adams R, Guren M, Sebag-Montefiore D . International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. J Clin Oncol. 2020; 38(22):2510-2518. PMC: 7406334. DOI: 10.1200/JCO.19.03266. View

Sterne J, Hernan M, Reeves B, Savovic J, Berkman N, Viswanathan M . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919. PMC: 5062054. DOI: 10.1136/bmj.i4919. View

Giani I, Mistrangelo M, Fucini C . The treatment of squamous anal carcinoma: guidelines of the Italian Society of Colo-Rectal Surgery. Tech Coloproctol. 2012; 17(2):171-9. DOI: 10.1007/s10151-012-0912-8. View

Steele S, Varma M, Melton G, Ross H, Rafferty J, Buie W . Practice parameters for anal squamous neoplasms. Dis Colon Rectum. 2012; 55(7):735-49. DOI: 10.1097/DCR.0b013e318255815e. View

10.

Geh I, Gollins S, Renehan A, Scholefield J, Goh V, Prezzi D . Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Anal Cancer. Colorectal Dis. 2017; 19 Suppl 1:82-97. DOI: 10.1111/codi.13709. View

11.

Tokar M, Bobilev D, Zalmanov S, Geffen D, Walfisch S . Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature. Onkologie. 2006; 29(1-2):30-2. DOI: 10.1159/000089798. View

12.

Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S . Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010; 102(7):1123-8. PMC: 2853094. DOI: 10.1038/sj.bjc.6605605. View

13.

Rao S, Guren M, Khan K, Brown G, Renehan A, Steigen S . Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(9):1087-1100. DOI: 10.1016/j.annonc.2021.06.015. View

14.

Sclafani F, Hesselberg G, Thompson S, Truskett P, Haghighi K, Rao S . Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review. J Surg Oncol. 2019; 119(4):489-496. DOI: 10.1002/jso.25320. View

15.

Brogden D, Kontovounisios C, Pellino G, Bower M, Mills S, Tekkis P . Improving outcomes for the treatment of Anal Squamous Cell Carcinoma and Anal Intraepithelial Neoplasia. Tech Coloproctol. 2019; 23(12):1109-1111. DOI: 10.1007/s10151-019-02121-8. View

16.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

17.

Sun M, Liu H, Yun Y, Yu Z, Yang F, Liu Y . Survival Benefit of Surgical Treatment Added Into Systemic Treatment for Isolated Breast Cancer Liver Metastases: A Systematic Review and Meta-Analysis. Front Surg. 2021; 8:751906. PMC: 8573018. DOI: 10.3389/fsurg.2021.751906. View

18.

Ott P, Elez E, Hiret S, Kim D, Morosky A, Saraf S . Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017; 35(34):3823-3829. DOI: 10.1200/JCO.2017.72.5069. View

19.

Morris V, Salem M, Nimeiri H, Iqbal S, Singh P, Ciombor K . Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017; 18(4):446-453. PMC: 5809128. DOI: 10.1016/S1470-2045(17)30104-3. View

20.

Fish R, Sanders C, Adams R, Brewer J, Brookes S, DeNardo J . A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. Lancet Gastroenterol Hepatol. 2018; 3(12):865-873. DOI: 10.1016/S2468-1253(18)30264-4. View